BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

Reuters

Apr 21, 2025

BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

April 21 (Reuters) - Gilead Sciences Inc GILD.O:

TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER
GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY
GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE $(SOC)$ IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS
GILEAD: OVERALL SURVIVAL $(OS)$, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS
GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC
GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES

Further company coverage: GILD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2529806872"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529806872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2529806872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-21 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529806872","market":"us","top_or_hot":-1,"title":"BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study</title></head><body><p><span>April 21 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER</p></li><li><p>GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY</p></li><li><p>GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)</p></li><li><p>GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS</p></li><li><p>GILEAD: OVERALL SURVIVAL <a href=\"https://laohu8.com/S/OS\">$(OS)$</a>, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS</p></li><li><p>GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC</p></li><li><p>GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES</p></li></ul><p>Further company coverage: <span>GILD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-21 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study</title></head><body><p><span>April 21 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER</p></li><li><p>GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY</p></li><li><p>GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)</p></li><li><p>GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS</p></li><li><p>GILEAD: OVERALL SURVIVAL <a href=\"https://laohu8.com/S/OS\">$(OS)$</a>, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS</p></li><li><p>GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC</p></li><li><p>GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES</p></li></ul><p>Further company coverage: <span>GILD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:1","article_id":"2529806872","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529806872","pubTimestamp":1745238609,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 StudyApril 21  - Gilead Sciences Inc GILD.O:TRODELVY PLUS KEYTRUDA DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCERGILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDYGILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE  IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFSGILEAD: OVERALL SURVIVAL , KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSISGILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+  MTNBCGILEAD: WILL CONTINUE TO MONITOR OS OUTCOMESFurther company coverage: GILD.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4516":"特朗普概念","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","BK4588":"碎股","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4532":"文艺复兴科技持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","GILD":"吉利德科学","LU0234570918.USD":"高盛全球核心股票组合Acc Close","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","MRK":"默沙东","BK4534":"瑞士信贷持仓"},"translate_title":"简介-吉利德报告3期Ascent-04/Keynote-D19研究的积极顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"MRK":0.9},"content_text":"BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 StudyApril 21 (Reuters) - Gilead Sciences Inc GILD.O:TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCERGILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDYGILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE $(SOC)$ IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFSGILEAD: OVERALL SURVIVAL $(OS)$, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSISGILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBCGILEAD: WILL CONTINUE TO MONITOR OS OUTCOMESFurther company coverage: GILD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}